期刊文献+

FLT3-ITD突变阳性急性髓系白血病的临床特征和预后因素 被引量:19

The clinical and prognostic significance of acute myeloid leukemia with FLT3-ITD
原文传递
导出
摘要 目的 探讨FLT3-ITD突变阳性急性髓系白血病(AML)的临床特征和预后因素,为FLT3-ITD突变阳性AML患者的预后评估提供更多证据.方法 收集98例FLT3-ITD突变阳性AML初诊患者的临床资料,对其临床特征与预后的相关性进行统计学分析.结果 98例FLT3-ITD突变阳性AML患者初诊时中位WBC 58.2 (0.3~ 461.8)×10^9/L,外周血原始细胞绝对计数中位数42.2(0~397.1)×10^9/L.71例细胞遗传学中高危组患者1个疗程完全缓解(CR)率为60.6%,原发耐药率为26.8%.单因素分析结果显示外周血原始细胞绝对计数低是影响患者1个疗程CR的良好预后因素(P=0.009).多因素分析结果显示,1个疗程达CR (HR=0.395,95% CI 0.183~0.850,P=0.001)及第1次CR期行异基因造血干细胞移植(HR=0.180,95%CI 0.043~0.752,P=0.018)是影响患者无复发生存的良好预后因素,1个疗程达CR(HR=0.251,95%CI 0.121~0.523,P<0.001)及外周血原始细胞绝对计数低(HR=0.219,95%CI 0.088~0.545,P=0.003)是影响患者总生存的良好预后因素.结论 外周血原始细胞计数低的FLT3-ITD突变阳性AML患者预后相对良好,1个疗程达CR和第1次CR期行异基因造血干细胞移植是改善FLT3-ITD突变阳性AML患者预后的重要治疗策略. Objective To investigate the clinical significance and prognosis factors of acute myeloid leukemia (AML) with FLT3 mutation-internal tandem duplication (FLT3-ITD) and provide more evidence for prognosis evaluation in AML with FLT3-ITD.Methods The clinical characteristics and outcomes of 98 AML with FLT3-ITD were analyzed.Results In patients with FLT3-ITD positive AML,the median of WBC and peripheral blood blast at initial diagnosis were 58.2 (0.3-461.8)× 10^9/L and 42.2 (0-397.1) × 10^9/L,respectively.The complete remission (CR) rate after one course induction therapy was 60.6% in 71 patients with intermediate or adverse risk.The primary refractory rate was 26.8% in 71 patients with intermediate or adverse risk.The lower number of peripheral blood blast was a favorable factor to achieve CR after one course induction therapy(P=0.009).CR after one course (HR=0.395,95% CI 0.183-0.85,P=0.001) and allo-transplantation in CR1 (HR=0.180,95% CI 0.043-0.752,P=0.018) favored longer relapse-free survival (RFS).CR after one course (HR=0.25 1,95% CI 0.121-0.523,P〈 0.001) and lower number of peripheral blood blast (HR=0.219,95% CI 0.088-0.545,P=0.003) favored longer overall survival (OS) in AML with FLT3-ITD.Conclusion FLT3-ITD positive AML with lower number of peripheral blood blast has a relative favorable prognosis.CR after one course and allotransplantation in CR1 are important strategy to improve prognosis in AML with FLT3-ITD.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2016年第12期1017-1021,共5页 Chinese Journal of Hematology
基金 国家自然科学基金重点项目(81430004) 天津市自然科学基金(15JCYBJC25700、15JCYBJC25000)
关键词 白血病 髓样 急性 基因 FLT3 DNA突变分析 预后 Leukemia, myeloid, acute Gene, FLT3 DNA mutational analysis Prognosis
  • 相关文献

参考文献2

二级参考文献21

  • 1Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study[J]. Cancer Res, 2001, 61(19):7233-7239.
  • 2Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials[J]. Blood, 2001, 98(6):1752-1759.
  • 3Deeb KK, Smonskey MT, Defedericis HC, et al. Deletion and deletion/insertion mutations in the juxtamembrane domain of the FLT3 gene in adult acute myeloid leukemia[J]. Leuk Res Rep, 2014, 3(2):86-89.
  • 4Borthakur G, Kantarjian H, Patel KP, et al. Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia[J]. Cancer, 2012, 118(23):5819-5822.
  • 5Shen Y, Zhu YM, Fan X, et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia[J]. Blood, 2011, 118(20):5593-5603.
  • 6Murphy KM, Levis M, Hafez MJ, et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay[J]. J Mol Diagn, 2003, 5(2):96-102.
  • 7Levis M, Murphy KM, Pham R, et al. Internal tandem duplications of the FLT3 gene are present in leukemia stem cells[J]. Blood, 2005, 106(2):673-680.
  • 8Moore AS, Faisal A, Gonzalez de Castro D, et al. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns[J]. Leukemia, 2012, 26(7):1462-1470.
  • 9Man CH, Fung TK, Ho C, et al. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation[J]. Blood, 2012, 119(22):5133-5143.
  • 10Shih LY, Huang CF, Wu JH, et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse[J]. Blood, 2002, 100(7):2387-2392.

共引文献191

同被引文献122

引证文献19

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部